Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 11/20 | 0.65 |
| ▸ | HTR1D | P28221 | 2/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.62 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007810 | 1.00 | HTR1B (0.65) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL667325 | 0.95 | KDM4E (0.61) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL667906 | 0.95 | KDM4E (0.61) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL10984843 | 0.91 | KCNA3 (0.69) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL5289923 | 0.90 | HTR1B (0.77) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL18574221 | 0.88 | HTR1B (0.47) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL11057929 | 0.86 | KCNA3 (0.54) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL8642238 | 0.84 | HTR1B (0.69) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL8674828 | 0.84 | HTR1B (0.69) | HTR1BHTR1DSLC6A4HRH1KCNA3 | |
| SCHEMBL9466089 | 0.84 | KDM1A (0.49) | HTR1BHTR1DSLC6A4HRH1KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111522198-B | Resist composition and pattern forming method | 信越化学工业株式会社 | 2024-01-26 | — | — | CN | disclosed |
| US-11840015-B2 | Composition for optical three-dimensional shaping, three-dimensionally shaped article, and method for producing same | OKAMOTO CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-12-12 | — | — | US | disclosed |
| EP-3904414-B1 | COMPOSITION FOR OPTICAL THREE-DIMENSIONAL SHAPING, THREE-DIMENSIONALLY SHAPED ARTICLE, AND METHOD FOR PRODUCING SAME | OKAMOTO CHEMICAL IND CO LTD (JP) | 2023-12-06 | — | — | EP | disclosed |
| CN-116360211-A | Chemically amplified positive photosensitive resin composition, protective film, and element having protective film | 奇美实业股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110963952-B | Onium salt, resist composition and pattern forming method | 信越化学工业株式会社 | 2022-10-21 | — | — | CN | disclosed |
| CN-110891980-B | Radical polymerization control agent and radical polymerization control method | 川崎化成工业株式会社 | 2022-09-30 | — | — | CN | disclosed |
| US-11448962-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| EP-3904414-A1 | COMPOSITION FOR OPTICAL THREE-DIMENSIONAL SHAPING, THREE-DIMENSIONALLY SHAPED ARTICLE, AND METHOD FOR PRODUCING SAME | Okamoto Chemical Industry Co., Ltd. (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-20210229344-A1 | COMPOSITION FOR OPTICAL THREE-DIMENSIONAL SHAPING, THREE-DIMENSIONALLY SHAPED ARTICLE, AND METHOD FOR PRODUCING SAME | OKAMOTO CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-07-29 | — | — | US | disclosed |
| CN-111522198-A | Resist composition and pattern forming method | 信越化学工业株式会社 | 2020-08-11 | — | — | CN | disclosed |
| US-7868036-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-01-11 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20080058320-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-03-06 | — | — | US | disclosed |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | US | disclosed |
| EP-1764099-A2 | Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV | Speedel Experimenta AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| CN-1934082-A | Organic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-21 | — | — | CN | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| CN-1117035-C | Water treatment agent | NIPPON CATALYTIC CHEM IND (JP) | 2003-08-06 | — | — | CN | disclosed |
| CN-1151380-A | Water treatment agent | NIPPON CATALYTIC CHEM IND (JP) | 1997-06-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066582-A1 | Diaminoalcohols as therapeutic compounds | CTSD, CTSL, CTSC | HTR1B 1359/4885HTR1D 1391/4885SLC6A4 3493/4885 |
| US-11448962-B2 | Resist composition and patterning process | PAG1, LIFR, GIGYF2 | HTR1B 4427/4885HTR1D 4701/4885SLC6A4 1901/4885 |
| US-20080058320-A1 | Organic Compounds | REN, AGTR1, ADH1C | HTR1B 517/4885HTR1D 698/4885SLC6A4 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.